This study suggests that the concomitant use of dabigatran, rivaroxaban, apixaban, P-gp, and enzyme-inducing AEDs may reduce the treatment efficacy and increase the risk of serious thrombotic and stroke events. The gene discussed is PGP; the disease is stroke disorder.